Investors & Media

WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each

CEO to participate on ovarian cancer panel and will highlight ACR-368, a DNA Damage Response (DDR) inhibitor in clinical testing for platinum-resistant advanced ovarian cancer and other solid tumors WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc.

WATERTOWN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each

The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted oncology agent for solid cancers  The OncoSignature® test will run on Akoya’s PhenoImager™ Solution

WATERTOWN, Massachusetts, June 22, 2022 – Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary proteomics-based technologies driving a new era of precision medicine,

WATERTOWN, Massachusetts,   April 20, 2022  –  Acrivon Therapeutics, Inc ., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced the appointments of Rasmus Holm-Jorgensen as the company’s chief financial officer,

WATERTOWN, Massachusetts, March 16, 2022  –  Acrivon Therapeutics, Inc ., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced that Peter Blume-Jensen, M.D., Ph.D., Acrivon’s chief executive officer and founder,

WATERTOWN, Massachusetts,   December 8, 2021  –  Acrivon Therapeutics, Inc ., a clinical-stage oncology therapeutics company with proprietary, proteomics-based technologies driving a new era of precision-based medicine, today announced the establishment of its scientific advisory board.

WATERTOWN, Massachusetts,   November 29, 2021  –  Acrivon Therapeutics, Inc ., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced that Peter Blume-Jensen, M.D., Ph.D., Acrivon’s chief executive officer and

WATERTOWN, Massachusetts, November 11, 2021 – Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced the successful completion of an oversubscribed $100 million Series B financing.